Improving Hospital-To-Methadone Clinic Connection Using Implementation Support for Patients With Opioid Use Disorder (HOTPIN-IF)
Facilitating In-Hospital Opioid Treatment Program Intakes to Support Hospital to OTP Linkage Among Hospitalized Patients With Opioid Use Disorder: An Implementation Trial in Four Hospitals
調査の概要
詳細な説明
The purpose of this study is to test whether a hospital-based approach can improve connection to methadone treatment after discharge. The approach includes completing OTP intake during hospitalization and supporting hospital teams through an implementation strategy called implementation facilitation (IF). This study also aims to understand how well the approach can be adopted and sustained across different hospitals. This is a multi-site clinical trial conducted at four hospitals. The study uses a hybrid type 2 implementation-effectiveness design, meaning it evaluates both patient outcomes and how the intervention is implemented. The study uses an incomplete stepped wedge cluster randomized design. In this design:
- All hospitals begin in a usual care phase
- Hospitals are randomly assigned a time to switch to the intervention
- Over time, each hospital transitions from usual care to the intervention phase
- This allows each hospital to serve as its own comparison
During the usual care phase, patients receive standard care, which includes referral to an OTP at discharge. During the intervention phase, hospital teams receive implementation support to help complete OTP intake during the hospital stay. The intervention is an implementation strategy designed to support hospital teams in completing OTP intake during hospitalization.
The study uses the RE-AIM framework to evaluate outcomes:
- Reach: The number and characteristics of patients who complete OTP intake and connect to care.
- Effectiveness: The primary outcome is connection to an OTP after hospital discharge (for example, within 7 days). Secondary outcomes may include engagement in treatment at 30 and 90 days, healthcare use, and mortality.
- Adoption: The proportion of hospital clinicians and teams who use the new workflows and complete OTP intake.
- Implementation: How well the intervention is delivered, including fidelity to core components, adaptations, and resources used.
- Maintenance: Whether the intervention is sustained over time after initial implementation.
The study will also assess implementation costs and identify barriers and facilitators to adoption.
Participants are adults with OUD who are hospitalized and interested in starting methadone treatment. Participants must be willing to connect to a methadone clinic after discharge.
Data will be collected from multiple sources, including:
- Electronic health records (EHRs) from participating hospitals
- Data from opioid treatment programs (when available)
- Study questionnaires completed during enrollment
- Administrative data on healthcare use
- National Death Index data for mortality outcomes
- Data will be combined across sites using a structured data approach to ensure consistency.
The analysis will evaluate:
- Differences in OTP connection rates
- Changes in treatment engagement over time
- Variation across hospitals
- Implementation outcomes and costs
- Qualitative data from interviews and observations may also be used to understand how the intervention works in real-world settings.
This study addresses a major gap in care for people with OUD. Improving connection to methadone treatment after hospitalization has the potential to reduce overdose deaths, improve health outcomes, and reduce healthcare use. By testing both effectiveness and implementation, this study will provide practical information for scaling this approach across hospitals.
If successful, this model could be widely adopted to improve access to life-saving treatment for people with OUD.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Susan L Calcaterra, MD, MPH, MS
- 電話番号:2487035947
- メール:susan.calcaterra@cuanschutz.edu
研究連絡先のバックアップ
- 名前:Sarah Mann, MA
- メール:sarah.mann@cuanschutz.edu
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Age ≥18 years
- Hospitalized with DSM-5 opioid use disorder, confirmed by clinical assessment
- Eligible for methadone treatment as determined by the clinical team
- Not currently enrolled in an Opioid Treatment Program (OTP)
- Anticipated discharge to the community
- Willing to initiate methadone and follow up at a partnering OTP
Exclusion Criteria:
- Current enrollment in an Opioid Treatment Program (OTP)
- Planned discharge to a correctional or institutional setting that precludes OTP follow-up
- Medical or psychiatric instability that precludes safe methadone initiation or completion of study procedures
- Inability to provide required information for OTP intake due to impaired cognition or altered mental status
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ヘルスサービス研究
- 割り当て:なし
- 介入モデル:クロスオーバー割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Usual Care
Standard hospital-to-OTP referral processes without implementation facilitation
|
Participants receive care at sites after rollout of Implementation Facilitation (IF) to support HOTPIN workflows. Focus on completing in-hospital OTP intake, including: Medical assessment Screening labs Methadone initiation Transportation coordination Supported by: External facilitators Learning collaboratives Workflow integration into the EHR |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
7-Day Hospital-to-OTP Linkage
時間枠:Measured within 7 days following hospital discharge
|
The primary outcome is whether a participant successfully connects to an Opioid Treatment Program (OTP) within 7 days after hospital discharge. Connection" (linkage) is defined as: Completion of OTP intake and/or attendance at the OTP, and Receipt or continuation of methadone treatment at the OTP |
Measured within 7 days following hospital discharge
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
30-Day OTP Engagement
時間枠:30 days after hospital discharge
|
Description: Proportion of participants who remain engaged in methadone treatment at an Opioid Treatment Program (OTP) within 30 days after hospital discharge. Defined by ongoing dosing or documented attendance at the OTP Reflects short-term treatment retention |
30 days after hospital discharge
|
|
90-Day OTP Engagement (Retention)
時間枠:Within 90 days after hospital discharge
|
Description: Proportion of participants who remain engaged in methadone treatment at an OTP within 90 days after hospital discharge. Defined by continued dosing records or clinic attendance Reflects longer-term treatment retention |
Within 90 days after hospital discharge
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Healthcare Utilization After Discharge
時間枠:90 days following hospital discharge
|
Description: Rates of emergency department visits and hospital readmissions following the index hospitalization. Assessed using hospital administrative and EHR data |
90 days following hospital discharge
|
|
All-cause mortality following hospital discharge.
時間枠:90 days after hospital disharge
|
Assessed using linkage to the National Death Index (NDI)
|
90 days after hospital disharge
|
協力者と研究者
捜査官
- 主任研究者:Susan L Calcaterra, MD, MPH, MS、University of Colorado, Denver
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 26-0455
- 1R01DA063733-01A1 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
We will share de-identified individual participant data (IPD) using a controlled access process (not open download)
We will require:
Data Use Agreement (DUA) IRB approval or exemption data security plan
We will exclude:
Direct identifiers Anything restricted under 42 CFR Part 2 without proper authorization
IPD 共有時間枠
Time Frame:
Data will be available beginning 12 months after publication of the primary results and ending 5 years after publication.
IPD 共有アクセス基準
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。